COMPASS Pathways plc CMPS
We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 psilocybin treatment, potentially a first in class treatment. COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.
We believe that our COMP360 psilocybin treatment could offer a new approach to treatment of serious mental health conditions, including treatment-resistant depression, or TRD, which is a subset of major depressive disorder, or MDD, post-traumatic stress disorder, or PTSD, and potentially many other serious mental health conditions.
CMPS is a depositary receipt: one CMPS stands for 1 share of this company, per the cover page of its latest 10-K. The market cap and the multiples above are stated per receipt; the statements below, including EPS, are as filed and are per underlying share.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $118.4M | $119.0M | $87.5M | $65.1M | $44.0M | $23.4M | $12.6M | — |
| SG&A | $60.6M | $59.2M | $49.4M | $45.4M | $39.2M | $28.0M | $8.6M | — |
| Total operating expenses | $179.0M | $178.2M | $136.9M | $110.4M | $83.2M | $51.4M | $21.2M | — |
| Operating income | -$179.0M | -$178.2M | -$136.9M | -$110.4M | -$83.2M | -$51.4M | -$21.2M | — |
| Interest expense | $4.5M | $4.5M | $2.2M | $0 | $0 | — | — | — |
| Pre-tax income | -$290.3M | -$153.5M | -$117.7M | -$91.1M | -$71.5M | -$60.3M | -$19.6M | — |
| Income tax | $2.5M | $1.6M | $780.0K | $408.0K | $199.0K | $32.0K | $15.0K | — |
| Net income | -$269.8M | -$155.1M | -$118.5M | -$91.5M | -$71.7M | -$60.3M | -$19.6M | — |
| EPS, basic | -3.08 | -2.30 | -2.32 | -2.16 | -1.79 | -3.55 | -2.62 | — |
| EPS, diluted | -3.08 | -2.30 | -2.32 | -2.16 | -1.79 | -3.55 | -2.62 | — |
| Shares, diluted (wtd. avg.) | 93.5M | 67.5M | 51.0M | 42.4M | 40.0M | 17.0M | 7.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $149.6M | $165.1M | $220.6M | $143.4M | $273.2M | $190.4M | $25.0M | $22.9M |
| Total current assets | $191.5M | $201.3M | $261.3M | $191.7M | $295.3M | $202.4M | $32.2M | — |
| Property, plant and equipment | — | $189.0K | $423.0K | $617.0K | $398.0K | $245.0K | $218.0K | — |
| Total assets | $210.3M | $213.7M | $276.0M | $197.3M | $300.9M | $203.5M | $32.4M | — |
| Accounts payable | $15.2M | $12.3M | $5.9M | $4.8M | $2.6M | $2.7M | $1.3M | — |
| Short-term debt | $17.5M | $5.5M | $0 | — | — | — | — | — |
| Total current liabilities | $247.8M | $34.0M | $19.6M | $15.6M | $15.1M | $6.9M | $23.9M | — |
| Long-term debt | $14.1M | $24.7M | $28.8M | $0 | — | — | — | — |
| Total liabilities | $263.2M | $59.0M | $50.2M | $16.0M | $16.5M | $6.9M | $23.9M | — |
| Retained earnings | -$822.6M | -$534.7M | -$379.6M | -$261.1M | -$169.6M | -$97.9M | -$37.6M | — |
| Total equity | -$52.8M | $154.7M | $225.7M | $181.3M | $284.4M | $196.6M | -$30.4M | -$14.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$157.2M | -$119.2M | -$97.4M | -$105.5M | -$67.7M | -$41.4M | -$17.8M | — |
| Depreciation and amortisation | $216.0K | $233.0K | $242.0K | $330.0K | $175.0K | $112.0K | $63.0K | — |
| Stock-based compensation | $13.6M | $19.5M | $17.3M | $13.1M | $8.6M | $18.0M | $3.3M | — |
| Capital expenditure | — | $0 | $66.0K | $596.0K | $334.0K | $131.0K | $165.0K | — |
| Investing cash flow | — | $0 | -$64.0K | -$596.0K | -$334.0K | -$628.0K | -$165.0K | — |
| Financing cash flow | $140.7M | $63.8M | $173.8M | $1.0M | $156.6M | $194.2M | $18.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-157123.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$19.6M | -$60.3M | -$71.7M | -$91.5M | -$118.5M | -$155.1M | -$269.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |